In the September 4, 2014, Federal Register, FDA announced its establishment of a public docket to discuss issues related to developing drugs for Duchenne Muscular Dystrophy. FDA received a proposed draft guidance from interested parties in June of this year and seeks additional guidance and public comment. Comments due October 6, 2014.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
